3.11
Envveno Medical Corporation Aktie (NVNO) Neueste Nachrichten
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference - ACCESS Newswire
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity - ACCESS Newswire
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R) - ACCESS Newswire
Westside Investment Management Inc. Acquires 116,650 Shares of enVVeno Medical Corporation (NASDAQ:NVNO) - MarketBeat
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth - Yahoo Finance
enVVeno Medical Corporation (NASDAQ:NVNO) Shares Bought by Geode Capital Management LLC - Defense World
Hancock Jaffe Laboratories, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 - Marketscreener.com
enVVeno Medical (NASDAQ:NVNO) and Sharps Technology (NASDAQ:STSS) Head to Head Survey - Defense World
Insider Buying: Francis Duhay Acquires Shares of enVVeno Medical Corp - GuruFocus.com
Envveno medical director Robert Gray buys $10,290 in shares - Investing.com India
Envveno medical director Duhay Francis buys $249,999 in stock By Investing.com - Investing.com Canada
Envveno medical director Robert Gray buys $10,290 in shares By Investing.com - Investing.com Australia
Envveno medical director Duhay Francis buys $249,999 in stock - Investing.com India
Insider Buying: Robert Gray Acquires 3,500 Shares of enVVeno Med - GuruFocus.com
enVVeno Medical Corporation (NASDAQ:NVNO) Director Purchases $10,290.00 in Stock - MarketBeat
Insider Buying: Sanjay Shrivastava Acquires Shares in enVVeno Me - GuruFocus.com
enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires $15,660.00 in Stock - MarketBeat
Envveno Medical's director Sanjay Shrivastava buys $15,660 in stock - Investing.com
Insider Buying: Matthew Jenusaitis Acquires 9,620 Shares of enVV - GuruFocus.com
Envveno medical director Matthew Jenusaitis buys $24,338 in stock By Investing.com - Investing.com Nigeria
Envveno medical director Matthew Jenusaitis buys $24,338 in stock - Investing.com India
Critical Survey: enVVeno Medical (NASDAQ:NVNO) versus Profound Medical (NASDAQ:PROF) - Defense World
NVNO stock touches 52-week low at $2.5 amid market challenges By Investing.com - Investing.com South Africa
NVNO stock touches 52-week low at $2.5 amid market challenges - Investing.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock By Investing.com - Investing.com Australia
CEO Robert Berman Increases Stake in enVVeno Medical Corp with R - GuruFocus.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock - Investing.com
enVVeno Medical completes final wave of implants in pre-clinical GLP study - TipRanks
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe - AccessWire
enVVeno Medical Completes Key Pre-Clinical Study for Revolutionary Venous Valve, Advances FDA Approval Path - StockTitan
NVNO Stock Touches 52-Week Low at $2.9 Amid Market Challenges - Investing.com
NVNO Stock Touches 52-Week Low at $3.01 Amid Market Challenges - Investing.com
enVVeno launches recap website highlighting VEITH Symposium participation - TipRanks
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - Kansas City Star
enVVeno Medical Showcases Breakthrough VenoValve Trial Data at VEITH Symposium | NVNO Stock News - StockTitan
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Reviewing enVVeno Medical (NASDAQ:NVNO) and Cerus (NASDAQ:CERS) - Defense World
PMA application submitted for VenoValve device - Venous News
enVVeno Medical (STU:5HJ) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
enVVeno Medical rises on submission of the venovalve PMA application for FDA approval - MSN
One-year data from the VenoValve US pivotal trial emerge - Venous News
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium - AccessWire
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):